Dr. JL was very upbeat in yesterdays performance and must remember that investors are not the only ones listening. It is likely that representatives of major pharmaceutical companies and oncology researchers track CytoDyn's investor calls and webcasts to stay informed about the clinical development of leronlimab, particularly for solid tumor cancers.
9